Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Mammary Gland Biology and Neoplasia
Published in: Journal of Mammary Gland Biology and Neoplasia 3/2017

01-09-2017

In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 3/2017

Login to get access

Abstract

Canine mammary tumors (CMTs) are the most common neoplasms in intact female dogs. Some clinical and molecular similarities between certain CMT subtypes and breast cancer make them a potential model for the study of the human disease. As misregulated Hippo signaling is thought to play an important role in breast cancer development and also occurs in CMTs, we sought to determine if Hippo represents a valid pharmacological target for the treatment of CMTs. Six CMT cell lines were assessed for their expression of the Hippo pathway effectors YAP and TAZ and for their sensitivity to verteporfin, an inhibitor of YAP-mediated transcriptional coactivation. Four cell lines that expressed YAP (CMT-9, −12, −28, −47) were found to be very sensitive to verteporfin treatment, which killed the cells through induction of apoptosis with ED50 values of 14–79 nM. Conversely, two YAP-negative cell lines (CF-35, CMT-25) were an order of magnitude more resistant to verteporfin. Verteporfin suppressed the expression of YAP/TAZ target genes, particularly CYR61 and CTGF, which play important roles in breast cancer development. Verteporfin was also able to inhibit cell migration and anchorage-independent growth. Likewise, verteporfin efficiently suppressed tumor cell invasiveness in the CMT-28 and -47 lines, but not in CF-35 cells. Together, our findings provide proof of principle that pharmacological targeting of the Hippo pathway compromises the viability and attenuates the malignant behavior of CMT cells. These results will serve as the basis for the development of novel chemotherapeutic approaches for CMTs that could translate to human medicine.
Literature
1.
Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, et al. Canine mammary tumours, an overview. Reprod Domest Anim. 2011;46(6):1112–31.CrossRefPubMed
2.
Benjamin SA, Lee AC, Saunders WJ. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol. 1999;36(5):423–36.CrossRefPubMed
3.
Sorenmo KU, Kristiansen VM, Cofone MA, et al. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 2009;7(3):162–72.CrossRefPubMed
4.
Withrow SJ, Vail DM. Withrow & MacEwen's small animal clinical oncology. 4th ed. St. Louis, Mo.: Saunders Elsevier; 2007. 1 texte électronique (xvii, 846 ) p.
5.
Meuten DJ, Moulton JE. Tumors in domestic animals. Fifth edition. ed. Ames, Iowa: Wiley Blackwell; 2017. viii, 989 pages p.
6.
Karayannopoulou M, Lafioniatis, S. Progrès récents chimiothérapie des tumeurs mammaires canines: examen des études de 2000 à ce jour. Revue de Médecine Vétérinaire. 2016;7–8(167):191–200.
7.
Simon D, Schoenrock D, Baumgartner W, et al. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med. 2006;20(5):1184–90.PubMed
8.
Klopfleisch R, von Euler H, Sarli G, et al. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol. 2011;48(1):98–116.CrossRefPubMed
9.
Marconato L, Lorenzo RM, Abramo F, et al. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol. 2008;6(2):90–101.CrossRefPubMed
10.
Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–57.CrossRefPubMed
11.
Johnson R, Halder G. The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13(1):63–79.CrossRefPubMed
12.
13.
Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.CrossRefPubMedPubMedCentral
14.
Zhao B, Li L, Wang L, et al. Cell detachment activates the hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012;26(1):54–68.CrossRefPubMedPubMedCentral
15.
Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 2012;13(9):591–600.CrossRefPubMed
16.
Low BC, Pan CQ, Shivashankar GV, et al. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014;588(16):2663–70.CrossRefPubMed
17.
Wada K, Itoga K, Okano T, et al. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011;138(18):3907–14.CrossRefPubMed
18.
19.
20.
Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287–312.CrossRefPubMed
21.
Morin-Kensicki EM, Boone BN, Howell M, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2006;26(1):77–87.CrossRefPubMedPubMedCentral
22.
Hossain Z, Ali SM, Ko HL, et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A. 2007;104(5):1631–6.CrossRefPubMedPubMedCentral
23.
Makita R, Uchijima Y, Nishiyama K, et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Ren Physiol. 2008;294(3):F542–53.CrossRef
24.
Vlug EJ, van de Ven RA, Vermeulen JF, et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 2013;36(5):375–84.CrossRef
25.
Chen Q, Zhang N, Gray RS, et al. A temporal requirement for hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 2014;28(5):432–7.CrossRefPubMedPubMedCentral
26.
27.
28.
Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34(6):681–90.CrossRefPubMed
29.
Cordenonsi M, Zanconato F, Azzolin L, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759–72.CrossRefPubMed
30.
Lamar JM, Stern P, Liu H, et al. The hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012;109(37):E2441–50.CrossRefPubMedPubMedCentral
31.
Shi P, Feng J, Chen C. Hippo pathway in mammary gland development and breast cancer. Acta Biochim Biophys Sin Shanghai. 2015;47(1):53–9.CrossRefPubMed
32.
Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68(8):2592–8.CrossRefPubMed
33.
Beffagna G, Sacchetto R, Cavicchioli L, et al. A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the hippo signalling pathway in canine and feline mammary tumours. Vet J. 2016;207:105–11.CrossRefPubMed
34.
Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2002;133(1):168–9.CrossRefPubMed
35.
Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110(4):667–73.CrossRefPubMed
36.
Wang C, Zhu X, Feng W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3sigma sequestering YAP in the cytoplasm. Am J Cancer Res. 2016;6(1):27–37.PubMed
37.
Wei H, Wang F, Wang Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of PDAC via disrupting the YAP-TEAD complex. Cancer Sci 2016.
38.
Feng J, Gou J, Jia J, et al. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9:5371–81.CrossRefPubMedPubMedCentral
39.
40.
Ma YW, Liu YZ, Pan JX. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res. 2016;6(12):2816–30.PubMedPubMedCentral
41.
Zhang H, Ramakrishnan SK, Triner D, et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal. 2015;8(397):ra98.
42.
Li H, Huang Z, Gao M, et al. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. J Exp Clin Cancer Res. 2016;35(1):134.CrossRefPubMedPubMedCentral
43.
Donohue E, Thomas A, Maurer N, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer. 2013;4(7):585–96.CrossRefPubMedPubMedCentral
44.
Lutful Kabir FM, Agarwal P, Deinnocentes P, et al. Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus. J Cell Biochem. 2013;114(1):56–66.CrossRefPubMed
45.
DeInnocentes P, Li LX, Sanchez RL, et al. Expression and sequence of canine SIRT2 and p53 genes in canine mammary tumour cells - effects on downstream targets Wip1 and p21/Cip1. Vet Comp Oncol. 2006;4(3):161–77.CrossRefPubMed
46.
Stokol T, Daddona JL, Mubayed LS, et al. Evaluation of tissue factor expression in canine tumor cells. Am J Vet Res. 2011;72(8):1097–106.CrossRefPubMed
47.
Abedini A, Zamberlam G, Lapointe E, et al. WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling. FASEB J. 2016;30(4):1534–47.CrossRefPubMed
48.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.CrossRefPubMed
49.
Santucci M, Vignudelli T, Ferrari S, et al. The hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem. 2015;58(12):4857–73.CrossRefPubMed
50.
Fu D, Lv X, Hua G, et al. YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors. Endocr Relat Cancer. 2014;21(2):297–310.CrossRefPubMedPubMedCentral
51.
52.
Maugeri-Sacca M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 2016;99:115–22.CrossRefPubMed
53.
54.
Tsai MS, Bogart DF, Castaneda JM, et al. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 2002;21(53):8178–85.CrossRefPubMed
55.
Jiang WG, Watkins G, Fodstad O, et al. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer. 2004;11(4):781–91.CrossRefPubMed
56.
Sanchez-Bailon MP, Calcabrini A, Mayoral-Varo V, et al. Cyr61 as mediator of Src signaling in triple negative breast cancer cells. Oncotarget. 2015;6(15):13520–38.CrossRefPubMedPubMedCentral
57.
Espinoza I, Menendez JA, Kvp CM, et al. CCN1 promotes vascular endothelial growth factor secretion through alphavbeta 3 integrin receptors in breast cancer. J Cell Commun Signal. 2014;8(1):23–7.CrossRefPubMed
58.
Harris LG, Pannell LK, Singh S, et al. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene. 2012;31(28):3370–80.CrossRefPubMed
59.
Xie D, Nakachi K, Wang H, et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001;61(24):8917–23.PubMed
60.
Wang MY, Chen PS, Prakash E, et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009;69(8):3482–91.CrossRefPubMed
61.
Chien W, O'Kelly J, Lu D, et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011;38(6):1741–7.PubMedPubMedCentral
62.
Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728–38.CrossRefPubMed
63.
Morishita T, Hayakawa F, Sugimoto K, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget. 2016;7(35):56241–52.CrossRefPubMedPubMedCentral
64.
Ciamporcero E, Shen H, Ramakrishnan S, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35(12):1541–53.CrossRefPubMed
65.
Hussain RN, Jmor F, Damato B, et al. Verteporfin photodynamic therapy for the treatment of choroidal haemangioma associated with Sturge-weber syndrome. Photodiagn Photodyn Ther. 2016;15:143–6.CrossRef
66.
Gupta R, Browning AC, Wu K, et al. Verteporfin photodynamic therapy for the treatment of persistent subfoveal choroidal neovascularization after external beam radiotherapy: one-year results. Am J Ophthalmol. 2005;139(3):561–2.CrossRefPubMed
67.
Mori R, Kelkar A, De Laey JJ. Photodynamic therapy with verteporfin in Belgian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Bull Soc Belge Ophtalmol. 2006;299:57–64.
68.
Tayanithi P, Pisankosakul P, Laksakapuk P. Treatment of subfoveal choroidal neovascularization secondary to age related macular degeneration with single treatment of verteporfin photodynamic therapy: a safety and short-term outcome. J Med Assoc Thail. 2004;87(Suppl 2):S78–82.
69.
70.
Likus W, Siemianowicz K, Bienk K, et al. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resist Updat. 2016;25:13–25.CrossRefPubMed
71.
Wang Z, Wu Y, Wang H, et al. Interplay of mevalonate and hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 2014;111(1):E89–E98.
72.
73.
Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357–66.CrossRefPubMed
74.
Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135(1):261–9.CrossRefPubMed
Metadata
Title
In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors
Publication date
01-09-2017
Published in
Journal of Mammary Gland Biology and Neoplasia / Issue 3/2017
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-017-9384-9
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits